share_log

哈三联(002900.SZ):部分药品拟中标集中采购

Harbin Medisan Pharmaceutical (002900.SZ): Some pharmaceuticals are proposed to be awarded in centralized procurement.

Gelonghui Finance ·  Dec 13 16:24

On December 13, Gelonghui reported that Harbin Medisan Pharmaceutical (002900.SZ) announced that the company and its wholly-owned subsidiary Lanxi Harbin Medisan Pharmaceutical Co., Ltd. (hereinafter referred to as "Lanxi Pharmaceutical") recently participated in the bidding for the 10th national centralized procurement organized by the National Organization of Pharmaceutical Concentrated Procurement and Use Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"). The company's pharmaceutical products, namely Esmolol Hydrochloride Injection, Theobromine Injection, and Potassium Chloride Injection, as well as Lanxi Pharmaceutical's product, Tandedrone Citrate Tablets, are expected to win the bid in this centralized procurement.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment